For over 30 years, Miltenyi Biotec has been a leading provider of products and services for clinical research and cell and gene therapy (CGT), enabling the delivery of new treatment options to patients with unmet medical needs. Today, over 2,500 patients are treated annually with cell products using Miltenyi Biotec technologies.

Our state-of-the-art products provide end-to-end integrated workflows for biomedical research and clinical applications, covering sample preparation, cell separation, cell activation, cell transduction and electroporation, cell culture, cell analysis, and cell sorting.

We develop well-characterized, tailored, and repeatable cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy® platform, to enable fully closed and automated manufacture of complex cellular products such as CAR NK cells, CAR T cells, TCR-transduced T cells, and gene-modified stem cells.